Tyra Biosciences Q2 net loss $13.3M; orphan drug designation for TYRA-300 in achondroplasia

Tyra Biosciences, Inc.

2023-Q2 EPS reported -$0.59

Net loss $13.3M vs $15.1M Q2 2022; cash & equivalents $232.4M as of June 30.
FDA granted Orphan Drug Designation for TYRA-300 for achondroplasia in July 2023.
SURF301 Phase 1/2 oncology study enrollment ongoing in Part A and Part B at U.S., EU, Australia sites.
TYRA-200 Phase 1 study in intrahepatic cholangiocarcinoma on track to dose first patient 2H 2023.
Strengthened leadership: appointed Dr. Michael Bober as VP Clinical Development and Medical Affairs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tyra Biosciences, Inc. reported the quarter ended June 30, 2023 results: net income Second quarter 2023 net loss was $13.3 million.

Period: the quarter ended June 30, 2023
Net income: Second quarter 2023 net loss was $13.3 million
Result: reported results

Exact text from the filing

Second quarter 2023 net loss was $13.3 million compared to $15.1 million for the same period in 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041368

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.